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Thyroidfolliclarceli tumor arise inrodents from mutations, perturbations ofthyroidandpitu-
itay hormone status with increased sution ofthyroid cell growth by thyroid-stimulating
hormone (TSH), oracombination ofthetwo. Theonlykown human thyroidcarcinogen is ion-
izing radiation. It is notknownfor certain whether chemicals thataffect thyroidcell growth lead
to human thyroid cancer. The U.S. Environmental Protection Agency applies the following sci-
encepolicypositions: 1) chemical inducedrodentthyroidtumors arepresumed to berelevntto
humans; 2)wheninterspecies information islacking thedefault is toasmecomparble carcino-
genicsenitivityin rodents andhumans; 3) adverserodentnoncancerthyroideffe due to chem-
ically induced thyroid-pituity disruption are presumed to be relevant to humans; 4) linear
dose-response considerations are applied to thyroid cancer induced by chemical substaces that
either do not disrupt thyroid functioning or lack mode ofaction information; 5) nonlinear thy-
roid cancer dose-response considerations are applied to chemicals that reduce thyroid hormone
levels, increase TSH and thyroid cell division, and are judged to lack mutanic acivity, and 6)
nonlinear conideions may be applied in thyroid cancer dose-response assessments on a case-
by-case basis for chemicalls that disrupt thyroid-pituitary functioning and demonstrate some
mutagenic activity. Required data for riskasessmentpurposes is mode ofaction information on
mutgenicity, increases in follicularcell growth (cell size and number) and thyroidglandweight,
thyroid-pituitary honrones, site ofaction, correlations between doses producing thyroid effects
and cancer, andreversibilityofeffet whendosing ceases. Key won iodide pump, microsomal
enzyme induction, 5'-monodeiodinase, ris assessment, thyroid follicular cell tumors, thyroid
hormone (T4, T3), thyroid p ida, throid-smulating hormone (TSH), UDP glucuronosyl
trnsferase. EnwronHealt Perspect106:447-457(1998). [Online29June 1998]
hbtap//ehpnal.niehs.nihgo.ldo/1998/106p447457hiWlbsaract.html
The U.S. Environmental Protection Agency
(EPA) conducts risk assessments on chemi-
cals for carcinogenicity under the guidance
provided in its cancer assessment guidelines
(1,2). From time to time, scientific develop-
ments cause the agency to reexamine proce-
dures that are generally applied. That is the
case with the review ofsome chemicals that
have produced thyroid follicular cell tumors
in experimental animals. In this paper, we
will present a summary ofthyroid carcino-
genesis and describe the procedures the
EPA will use to evaluate these tumors and
the data that are needed to make these
judgments. Experience in applying the thy-
roid policy to a set of pesticides has been
reported (3).
The proposed EPA cancer assessment
guidelines () generally operate on the rebut-
table premise that findings of chemically
induced cancer in laboratory animals signal
potential hazards in humans. Likewise, for
dose-response analyses, the guidelines first
call for use ofthe most biologically appropri-
ate means for dose extrapolation. In the
absence of such knowledge, assessors are
directed toward the use of default science
policy positions, either low-dose linear,
nonlinear, or both procedures. Male rat kid-
ney tumors due to accumulation of ax2u-
globulin were the first instance in which the
EPA developed generic guidance for the
assessment ofa specific tumor type (4); thy-
roidtumors are the second.
Although the present effort is directed
specifically at tumors ofthe thyroid follicu-
lar cells, it is recognized that endocrine
organs that secrete hormones into the
blood or lymph respond to stimuli via
common pathways, and other organs may
develop tumors by disruption ofhormonal
balance. Therefore, it may be possible that
some ofthe lessons learned with the analy-
sis ofthyroid follicular cell tumors will be
applicable to other endocrine tumor sites
in the future (5,6).
In 1988, the EPA developed a review
ofthe existing science on thyroid follicular
cell carcinogenesis and a draft science poli-
cy position covering the evaluation of
chemicals that have induced thyroid
tumors in experimental animals. The exter-
nal EPA Science Advisory Board approved
the science review (7) and tentatively
embraced the policy position that
dose-response relationships for some thy-
roid tumors could be assessed using nonlin-
ear considerations. After revision and a sec-
ond review, the policy document was final-
ized (8). This paper presents the underlying
science policy for thyroid follicular cell
tumors.
Overview of Thyroid
Carcinogenesis
Circulating thyroid hormone determines
the level of operation of most cells of the
body (9); too much or too little hormone
results in disease. Control ofthe concentra-
tion of this endocrine hormone in the
blood is mainly regulated by a negative
feedback involving three organs: the thyroid
gland, which produces thyroid hormone,
and the pituitary gland and hypothalamus,
which respond to and help maintain opti-
mal levels ofthyroid hormone (Fig. 1). The
hypothalamus stimulates the pituitary
through thyrotropin-releasing hormone
(TRH) to produce thyroid-stimulating hor-
mone (TSH), which then prompts the thy-
roid gland to produce thyroid hormone.
The stimulated thyroid actively transports
inorganic iodide into the follicular cell and
converts it to an organic form and then into
thyroid hormone molecules, which can
influence target organs throughout the
body. Thyroid hormone, in tissues periph-
eral to the thyroid, can be converted from a
less active thyroxine (T4) to a more active
triiodothyronine (T ) form. Thyroid hor-
mone is also metaboized by the liver, large-
ly by conjugation reactions, and excreted
into the bile.
Cells in the hypothalamus and pituitary
gland respond to levels ofcirculating thyroid
hormone, such that when thyroid hormone
levels are high, there is a signal to reduce the
output of TRH and TSH. Likewise, when
thyroid hormone levels are reduced, the
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Figure 1. Hypothalamic-pituitary-thyroid axis.
Abbreviations: TRH, thyrotropin-releasing hor-
mone; TSH, thyroid stimulating hormone; T3, tri-
iodothyronine; T4,thyroxine.
hypothalamus and pituitary are prompted
to deliver more TSH to the thyroid gland
to increase the output ofthyroid hormone.
This negative feedback loop helps the body
to respond to varying demands for thyroid
hormone and to maintain hormone home-
ostasis. Circulating T4, T3, and TSH can
readily be monitored in the serum ofexper-
imental animals and humans by radioim-
munoassay and serve as biomarkers ofexpo-
sure and effect of agents that disrupt thy-
roid-pituitary status.
In mammals, when demands for more
thyroid hormone are small, existing thyroid
follicular cells can meet the demand. With
increased need, as a result ofcertain chemi-
cal exposures or iodide deficiency, the thy-
roid responds by increasing the size (hyper-
trophy) and number (hyperplasia) ofthy-
roid follicular cells to enhance hormone
output. With continued TSH stimulation
there is actual enlargement of the thyroid
gland (goiter) and, at least in rodents, even-
tually neoplasia of the thyroid follicular
cells. Since TSH-producing pituitary cells
are also stimulated, they too sometimes
undergohyperplasia andneoplasia.
For details about thyroid follicular cell
carcinogenesis, consult Hill et al. (7) and an
update ofthe science since 1988 (10), as well
asanumberofrelevant reviews (11-25). Rich
historicalliterature isalsovaluable(26-33).
Role ofTSH in Rodent
Carcinogenesis
Several experimental findings in rodents
that perturb thyroid-pituitary homeostasis
and lead to elevated TSH levels indicate
the central role ofTSH in inducing thyroid
carcinogenic effects: 1) loss ofthyroid cells
through partial thyroidectomy led to a sus-
tained inability ofthe thyroid to meet the
demands for thyroid hormone; 2) iodide
deficiency decreased the thyroid's ability to
synthesize adequate supplies of thyroid
hormones; and 3) transplantation of pitu-
itary tumors that autonomously secrete
TSH added more of the trophic hormone
to graft recipients (7). These experimental
manipulations were done in the absence of
any exogenous chemical treatment but
demonstrate the seminal qualitative role
that TSH plays in thyroid carcinogenesis.
Quantitatively, its significance is demon-
strated by the correlation between the TSH
level and the number of tumors/gland in
an initiation-promotion study (15).
If a goitrogenic stimulus that would
lead to thyroid tumor formation in rodents
is removed early in the process, effects
reverse toward normal (34). Likewise, if a
goitrogenic stimulus is given in conjunc-
tion with adequate amounts of exogenous
thyroid hormone (35) or after hypophysec-
tomy to remove TSH-secreting cells (36),
then hypertrophy, hyperplasia, and tumors
of the thyroid do not develop. It follows
from these observations that ifTSH levels
are chronically elevated, there will be thy-
roid cell hypertrophy, hyperplasia, and
some potential for neoplasia, but under
conditions where thyroid-pituitary home-
ostasis is maintained, the steps leading to
tumor formation are not expected to devel-
op, and the chances oftumor development
are negligible.
Genetic Influences
Rodent studies indicate an interplay
between genetic and nongenetic events in
the development of thyroid tumors.
Evidence indicates that carcinogenesis
often proceeds through a number ofopera-
tional steps: initiation, promotion, and
progression (37). Initiation seems linked to
genetic events with the induction of DNA
mutations, whereas promotion includes at
least nongenetic events that lead to the
expansion of a clone of initiated cells via
repeated cell division. Progression is associ-
ated with the accumulation of cell behav-
iors (such as enzymatic destruction ofbase-
ment membranes and increased mobility)
that allow cells to invade locally and metas-
tasize distally, probably in part due to still
other mutations. Some genetic influences
do not result in mutations, but in changes
in gene expression that can affect the car-
cinogenic process.
Treatment regimens that produce thy-
roidtumors in rodents can beconceptualized
in regard to initiation and promotion. These
stepsdo notthemselves describe carcinogenic
mechanisms but, instead, present a frame-
workforviewingexperimental findings.
*In two-stage experiments in which a
mutagenic agent such as radioactive
iodide is followed by treatment with a
nonmutagenic goitrogen (e.g., a chemical
inhibitor of thyroid hormone synthesis),
the first agent acts like an initiator and
the second behaves as a promoter (38).
*When treatment with a goitrogen alone
leads to tumor formation, TSH increases
cell division among normal cells, which
leads to increases in the overall chance ofa
spontaneous initiating mutation, and then
promotes the altered cells, which retain
responsiveness to TSR; carcinogenesis in
these cases would be free of chemically
induced mutagenic effects (39).
*Some chemicals appear to have both initi-
ating and promoting activity, as they are
mutagenic in many test systems and have
significant antithyroid activity (e.g., 4,4'-
oxydianiline) (40).
* Still other agents, such as x irradiation (41)
and certain chemicals (e.g., some nitrosa-
mines) (42), are definitely mutagenic but
lackintrinsicgoitrogenic activity.
These agents can easily initiate the car-
cinogenic process, but tumor formation
would be independent ofstrongpromotional
activity from antithyroid effects. TSH may
still playapermissive role, as these agents can
induce cell injury and cell death, which lead
to reductions in the output ofthyroid hor-
mone and increases in TSH-induced cell
division ofinitiated thyroid cells.
It thus appears that thyroid cancer in
experimental animals may be due to muta-
genic influences that lead to DNA changes
(X rays, 1311, mutagenic chemicals), to hor-
mone perturbation that leads to growth
stimulation, or both. Hormone perturba-
tion directly increases the number of thy-
roid cells and indirectly leads to mutations
(partial thyroidectomy, transplantation of
TSH-secreting pituitary tumors, iodide
deficiency, chemicals inhibiting iodide
uptake by the thyroid, chemicals inhibiting
thyroid peroxidase, chemicals inhibiting
release of thyroid hormone from the thy-
roid gland, chemicals damaging thyroid fol-
licular cells, chemicals inhibiting conversion
ofT4 to T3, chemicals increasing hepatic
thyroid hormone metabolism and excre-
tion). In those cases where increases in cell
number are dominant, the inciting agent or
procedure may be seen as the carcinogenic
stimulus, but the proximate carcinogenic
influence is TSH. For those with a domi-
nant mutagenic influence, TSH may play
an enhancing role in the carcinogenic
process.
Possible Mechanistic Steps
The precise molecular steps in the carcino-
genic process leading to thyroid follicular cell
cancer have not been totally elucidated,
although significant insights into theproblem
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have been described (25,43). Normal cell
division in thethyroidseems tobeaffected by
an interplay among several mitogenic factors,
namely TSH, insulin-like growth factor 1
(IGF-1), insulin, epidermal growth factor
(EGF), and possibly fibroblast growth factor
(FGF). Stil other factors such as transform-
ing growth factor , (TGFP), certain interfer-
ons, andinterleukin 1 mayinhibitgrowth.
TSH communicates with the cell's interi-
or byactivating adenylate cydase to raise lev-
els ofcyclic AMP. It also functions through
the phosphatidyl-inositol/Ca2+ signal trans-
duction cascade, which activates phospholi-
pase C. This latter system expresses itself
through two pathways: inositol triphosphate,
which releases calcium from cellular stores,
and 1,2-diacylglycerol, which activates pro-
tein kinase C. Signal transduction continues
following protein kinase C activation through
several steps, including the rasprotooncogene
and various kinases, culminating in the acti-
vation ofnuclear transcription factor genes
(e.g., c-fs), which leads to cellular prolifera-
tion. The diacylglycerol pathway may
account for the fact that the phorbol ester
tumor promoters, which increase protein
kinaseC, also stimulate thyroidcell division.
EGF, insulin, and IGF-1 act through
tyrosine kinase receptors. TSH increases
EGF binding to its receptor and enhances
cell division. IGF-1 and high doses of
insulin may influence the TSH receptor.
Iodide decreases thyroid cell adenylate
cyclase and calcium levels, and reduced
iodide enhances TSH effectiveness. In sum,
the actual control ofnormal cell division in
follicular cells may, in fact, represent some
interaction ofall these factors and possibly
othergrowth regulatorysubstances.
Under conditions of thyroid-pituitary
imbalance, there is no question that TSH
plays a significant role in stimulating DNA
synthesis and cell proliferation; however,
there is a controversy concerning the extent
that normal follicular cells can proliferate.
One research group claims that cells have
limited capacity to respond to the growth-
inducing effects ofTSH (44). In this case,
tumor formation would entail mutational
steps that free cells from their growth limit-
ing potential. Another group of investiga-
tors thinks that follicular cells are innately
heterogeneous, with some of them having
stem cell-like proliferation potential while
others are more restricted (45). The stem
cell-like follicular cells would continue to
respond to TSH stimulation andeventually
give rise to tumors. It seems possible that
both positions might actuallyapply.
Neoplastic transformation appears to
occur in single cells that then expand clonal-
ly. Under TSH stimulation, the yield of
mutations that may influence transformation
increases, even in the absence ofan increase
in the mutation rate per cell. This is because
the repeated cell divisions lead to an
increased number of cells at risk for muta-
tion, or rapid cell turnover leaves some spon-
taneous DNAdamageunrepaired.
The precise genetic alterations that
accumulate in thyroid follicular cells have
not been clearly established in humans or
in experimental systems, although muta-
tions involving the ras protooncogene, the
p53 tumor suppressor gene, and various
chromosome aberrations have been report-
ed in the follicular variety of epithelial
tumors. These changes in gene expression
could lead to uncontrolled cellular growth
and allow cells to attain the ability to
invade adjacent tissues and metastasize
(Fig. 2). For the papillary variety ofthyroid
epithelial tumors, changes in expression of
other factors have been noted, namely pro-
tooncogenes PTC/ret, trk, and met(25,43).
Transformed rodent cells that are stim-
ulated to proliferate under the influence of
continuing antithyroid stimulation retain
their responsiveness to TSH. Interestingly,
human thyroid cancer cells often retain
TSH receptors and the ability to respond
to TSH, although their receptors dissipate
as tumors become more anaplastic. Tumor
cells that attain maximal malignant poten-
tial usually lose their dependence on TSH.
Although interesting observations concern-
ing growth regulation associated with thy-
roid carcinogenesis have been made, clearly
morework is needed.
HumanThyroid Carcinogenesis
Clinically manifest thyroid cancer in
humans in the United States is uncommon
andlargelynonfatal; onlyabout 17,200 new
cases occur each year (an incidence rate of
around 3 per 100,000 persons, with about
1,200 deaths annually (>90% 5-year sur-
vival, which constitutes only around 0.5%
ofall cancer deaths) (46,47). In contrast to
clinically apparent disease, small occult thy-
roid cancers are noted at autopsy in a small
percentage of persons in a number of sur-
veys and up to about 50% in other investi-
gations (48,4p). The incidence in autopsy
studies is more like that noted in rats in the
National Toxicology Program, where about
0.4% ofcontrol rats are diagnosed with thy-
roid cancers at 2 years ofage (50). However,
this comparison is somewhat misleading.
Detailed histological examinations of
human and rodent thyroids are not routine-
ly performed by all investigators.
Histological criteria for tumors differ over
time and across reviewers. In addition, thy-
roid follicular cell cancer in humans is most
often diagnosed histologicly as a papillary
pattern and less often as a follicular pattern,
TSH,insulin,IGF-1,EGF,FGF
ras,Chromosome aberrations
of5,7 and 12. gap
Lossofheterozygosity at3p
roid (follicular) carcinogenesis. Abbreviations:
TSH, thyroid-stimulating hormone; IGF-1, insulin-
like growth factor 1; EGF, epidermal growth fac-
tor; FGF, fibroblast growth factor; gsp, GTP-bind-
ing protein mutation.
whereas in rodents the follicular cell tumors
are of a follicular pattern. The aggressiveness
of tumors varies: rodent thyroid neoplasms
rarely metastasize; human cancers frequently
metastasize. These differences regarding his-
tology, along with the shortcomings of
information from descriptive and analytical
epidemiologic investigations, help to
emphasize the diffilculty in comparing
human and rodent cancer incidence data.
For years, the only known human thy-
roid carcinogen was x irradiation, which
caused an increase in papillary tumors
(41,51). It was questioned whether ionizing
radiation from diagnostic or therapeutic use
of 1311 was carcinogenic in humans (52,53),
although more recently, children exposed to
radioiodine (1311) following the Chernobyl
reactor accident in the Ukraine have devel-
oped thyroid cancer; iodide deficiency is
also common in the region and may aug-
ment the response to 1311I (54). Most of the
human chemical carcinogens appear to be
mutagenic and cause tumors in more than
one site; some are steroid hormones. To
date, no chemical has been identified as
being carcinogenic to the human thyroid.
Rumans respond as do experimental ani-
mals in regard to short- and mid-term distur-
bances in thyroid functioning from various
antithyroid stimuli such as iodide deficiency,
partial thyroidectomy (surgically or 1311
induced), and goitrogenic chemicals (e.g.,
thionamides): when circulating thyroid hor-
mone levels go down, the TSR level rises and
induces thyroid hypertrophy and hyperplasia.
Rowever, the long-term consequences of
antithyroid action are harder to interpret,
and there is controversy regarding whether
the enlarged human thyroid gland undergoes
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conversion to cancer. Thyroid enlargements
and nodules have been implicated as possi-
ble antecedents to thyroid cancer in
humans, but direct evidence of conversion
of these lesions to malignancy is lacking.
The evidence that does exist for possible
conversion of preneoplastic to neoplastic
lesions is only indirect in nature. Persons
who live in iodide-deficient areas of the
world are unable to synthesize adequate lev-
els of thyroid hormones; they develop ele-
vated TSH levels, very enlarged thyroid
glands, and lesions typified as adenomatous
hyperplasia. There is conflicting evidence
whether thyroid cancer is increased in these
people (55,56). In contrast to these observa-
tions, it seems that domestic animals but
not wild animals in iodide deficient areas
developed elevated incidences of thyroid
tumors (57), and tumor incidence disap-
peared in dogs following the advent of
using iodized salt (58). Iodide may have
some influence on the histological type of
thyroid cancer, with follicular being more
common in iodide deficient areas and papil-
lary being more common in iodide rich
areas (59). People with various inborn
errors ofmetabolism that are unable to syn-
thesize enough effective thyroid hormone
develop very enlarged thyroids, but few
cases of cancer have been reported. There
are no reports of thyroid tumors among
persons with resistance to thyroid hormone
(60,61). In persons with the autoimmune
disorder Graves' disease, there are often
immunoglobulins that stimulate thyroid
cells in ways analogous to TSH, even
though TSH levels per se are very low. It is
not known whether there is an increase in
thyroid cancer among these patients; some
studies seem to indicate either that cancer
incidence may be increased or that thyroid
tumors in these patients may be more
aggressive (62,63). Overall, this qualitative
information suggests that prolonged stimu-
lation of the human thyroid under certain
circumstances may lead to cancer, as in the
presence of inherited metabolic conditions
or long-term immunologic abnormalities,
but there is uncertainty in this conclusion.
In epidemiologic studies, goiter and
thyroid nodules have been shown to be risk
factors for thyroid cancer. The specific
causes ofthese enlargements are not known
but, where studied, do not appear to be
due to hypothyroidism (64,65). Some
researchers believe that part of the associa-
tion may be due to the close medical scruti-
nygiven to persons with suspicious thyroid
enlargements (66,67).
In spite ofthe potential qualitative sim-
ilarities, there is evidence that humans may
not be as quantitatively sensitive to thyroid
cancer development from thyroid-pituitary
450
disruption as rodents. Rodents readily
respond to reduced iodide intake with the
development of cancer; humans develop
profound hyperplasia with adenomatous
changes with only suggestive evidence of
malignancy. Even with congenital goiters
due to inherited blocks in thyroid hormone
production, only a few malignancies have
been found in humans.
The reasons for differences in perceived
interspecies sensitivity are not fully known.
However, one factor that may play a role in
interspecies quantitative sensitivity to thyroid
stimulation deals with the influence ofpro-
tein carriers ofthyroid hormone in the blood
(Table 1). Both humans and rodents have
nonspecific low affinity protein carriers of
thyroid hormone (e.g., albumin). However,
in humans, other primates, and dogs there is
a high affinity binding protein, thyroxine-
bindingglobulin, which bindsT4 (andT3 to
a lesser degree); this protein is missing in
rodents and lowervertebrates. As a result, T4
bound to proteins with lower affinity in the
rodent is more susceptible to removal from
the blood, metabolism, and excretion from
the body. In keeping with this finding, the
serum half-life ofT4 is much shorter in rats
(<1 day) than in humans (5-9 days); this dif-
ference in T4 half-life results in a 10-fold
greater requirement for endogenous T4 in
the rat thyroid than in theadulthuman (68).
Serum T3 levels also show a species differ-
ence; the half-life is around 6 hr in rats and
24 hr in humans (69,70). There is a mor-
phological consequence to these hormone
differences. High thyroid hormone synthetic
activity is demonstrated in follicles in
rodents: they are relativelysmall, surrounded
often bycuboidal epithelium. Follicles inpri-
mates demonstrate less activity and are large
with abundant colloid, and follicular cells are
relativelyflattened (lowcuboidal) (16).
The accelerated production of thyroid
hormone in the rat is driven by serum TSH
levels that are probably about 6- to 60-fold
higher than in humans. This assumes a basal
TSH level in rats and humans of200 ng/ml
and 5 pU/mI, respectively, and a potency of
human TSH of 1.5-15 U/mg ofhormone
(71). Thus, itappears that the rodent thyroid
gland is chronically stimulated byTSH levels
to compensate for the increased turnover of
thyroid hormone. It follows that increases in
TSH levels above basal levels in rats could
more readily move the gland toward
increased growth and potential neoplastic
change than in humans. Interestingly, adult
male rats have higher serum TSH levels than
females (72, and they are often more sensi-
tive to goitrogenic stimulation and thyroid
carcinogenesis. In humans, there is no sex
difference in hormone levels, but females
morefrequently develop thyroid cancer (46).
In addition to considerations about the
influence of serum thyroid hormone carrier
proteins, there are differences between
humans and animals in size, lifespan, basal
metabolic rate, and pharmacokinetics and
pharmacodynamics of endogenous and
exogenous chemicals. Any comparison of
thyroid carcinogenic responses across species
should be cognizant ofall these factors.
The guidance given here on thyroid
tumors is not unique. Other authorities have
recognized and incorporated advances in the
understanding about carcinogenic mecha-
nisms into their assessments of cancer risks
(73-78).
Science Policy Guidance
Position Statements
Rodents andhumans share a common phys-
iology in regard to the thyroid-pituitary
feedback system. Short-term perturbation in
this system often leads to similar effects in
both groups, resulting in increases and
decreases in circulating thyroid andpituitary
hormones. It is well established in rodents
that disruption of thyroid-pituitary status
with elevation of TSH levels is associated
with thyroid tumor and sometimes related
pituitary tumor development. This is true
whether it is due to deficiency in iodide,
reduction in thyroid mass, presence ofTSH-
producing pituitary tumors, or administra-
tion ofgoitrogenic chemicals. An increase in
TSH stimulation of the thyroid is a final
common development. Likewise, adminis-
tration of exogenous thyroid hormone or
removal of a TSH-increasing stimulus
reduces theeffects in the thyroid.
The role of thyroid-pituitary disruption
in cancer development in humans is much
less convincing than in animals. Iodide defi-
ciency has been associated with increases in
thyroid cancer in some studies but not in
Table1.Interspecies and intraspecies differences
Parameter Human Rat
Thyroxine binding Present Essentially
globulin absent
T4 half-life 5-9 Days 0.5-1 Day
T3 half-life 1 Day 0.25 Day
T4 production rate/ 1x 10xthat in
kg bodyweight humans
Serum TSH 1x 6-60xthatin
humans
Follicular cell Low cuboidal Cuboidal
morphology
Sex differences
Serum TSH M = F M<2xF
Cancer sensitivity F = 2.5x M M > F
Abbreviations: T4, thyroxine; T3, triiodothyronine; TSH,
thyroid stimulating hormone; M, male; F, female.
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others. Similarly an association between either
inborn errors ofmetabolism affecting thyroid
hormone output or autoimmune-related
Graves' disease and cancer has been suggested
but not proven. TSH may at least play some
permissive role in carcinogenesis in humans.
Accordingly, wecannotqualitativelyreject the
animal model; itseems reasonable that it may
serve as an indicator ofa potential human
thyroid cancerhazard. However, to theextent
that humans are susceptible to the tumor-
inducing effects ofthyroid-pituitary disrup-
tion and given that definitive human data are
not available, humans appear to be quantita-
tivelyless sensitive than rodents to developing
cancer from perturbations in thyroid-pitu-
itary status. Recognizing these things and
based upon thyroid carcinogenesis mode of
action considerations, the EPA adopted the
followingthreesciencepolicypositions:
1. It is presumed thatchemicals thatproduce
rodent thyroid tumors may pose a car-
cinogenic hazard forthehuman thyroid.
2. In the absence ofchemical-specific data,
humans and rodents are presumed to be
equally sensitive to thyroid cancer due to
thyroid-pituitary disruption. This is a
conservative position when thyroid-pitu-
itary disruption is the sole mode of
action in rats because rodents appear to
be more sensitive to this carcinogenic
mode ofaction than humans. When the
thyroid carcinogen is a mutagenic chemi-
cal, the possibility that children may be
more sensitive than adults needs to be
evaluated on acase-by-case basis.
3. Adverse rodent noncancer thyroid effects
(e.g., thyroid gland enlargements) follow-
ing short- and long-term reductions in
thyroid hormone levels are presumed to
posehuman noncancer health hazards.
Some chemicals that have produced thy-
roid follicular cell tumors in laboratory
rodents appear to work by producing a dis-
turbance in thyroid-pituitary homeostasis,
others appear to act primarily through a
mutagenic mode of action, and still others
seem to show a combination ofboth modes
Table 2. Default dose-response procedures for
thyroid carcinogens
Arrayofdata Dose-
Example Antithyroid Mutagenic methodology
1 Unknown Unknown Linear
2 No Yes Linear
3 Yes No Nonlinear
(MOE)
4 Yes Yes Linear and
nonlinear
(MOE)
MOE, margin of exposure.
ofaction. The question then becomes how
to evaluate the risks of thyroid tumors for
humans given exposure to any of these
chemicals. If the animal tumors are due to
chemical doses that produce imbalances in
thyroid-pituitary functioning, the chance of
cancer is anticipated to be minimal under
conditions of hormonal homeostasis.
Tumors that seem to arise from relevant
mutagenic influences (e.g., gene mutations
and structural chromosome aberrations)
without perturbation in thyroid-pituitary
status maypose some chance ofcancer across
abroader rangeofdoses. Consequently, until
such time that biologically based models and
data become available, the EPA has adopted
five other science policy positions for con-
ducting dose-response assessments ofchemi-
cal substances that have produced thyroid
follicular cell (and related pituitary) tumors
in experimental animals:
1. A linear dose-response procedure should
be assumed when needed experimental
data to understand the cause of thyroid
tumors are absent and the mode of
action is unknown (Table 2, Example 1).
2. A linear dose-response procedure should
be assumed when the mode of action
underlying thyroid tumors is judged to
involve mutagenicity alone (Table 2,
Example 2).
3. A nonlinear dose-response relationship
(marginofexposure) should be usedwhen
thyroid-pituitary disruption is judged to
be the sole mode ofaction ofthe observed
thyroid and related pituitary tumors
(Table 2, Example 3). Thyroid-pituitary
perturbation is not likely to have carcino-
genic potential in short-term or highly
infrequent exposure conditions. The mar-
gin of exposure procedure generally
should be based on thyroid-pituitary dis-
ruptive effects themselves, in lieu oftumor
effects, when data permit. Such analyses
will aid in the development ofcombined
noncancer and cancer assessments oftoxi-
city. Results of the margin of exposure
procedure will be presented in a way that
supports risk management decisions for
exposure scenarios ofdiffering types (e.g.,
infrequent exposure, short durations).
4. Consistent with EPA risk characteriza-
tion principles, both linear and margin of
exposure considerations should be
assumed when both mutagenic and thy-
roid-pituitary disruption modes ofaction
are judged to be potentially at work
(Table 2, Example 4). The weight ofevi-
dence for emphasizing one over the other
should also be presented. The applicabili-
ty of each to different exposure scenarios
should be developed for risk management
consideration.
5. Dose-response relationships for neo-
plasms other than the thyroid (or pitu-
itary) should be evaluated using mode of
action information bearing on their
induction and principles laid out in cur-
rent EPA cancer risk assessment guide-
lines. There is an association between
thyroid and liver tumors in rodent cancer
studies (79,80). The reason(s) for this
relationship has not been generically
established but should be carefully
assessed for chemicals on a case-by-case
basis. Some may be due to induction of
hepatic microsomal enzymes.
Most of the focus in implementing
this policy is devoted to answering the fol-
lowing questions: 1) Does an agent that
shows thyroid carcinogenic effects have
antithyroid activity? 2) Can modes of
action other than thyroid-pituitary dis-
ruption account for thyroid tumor forma-
tion by this chemical? and 3) How can
one express thyroid dose-response rela-
tionships? Adequately answering these
questions is dependent upon a data-rich
information base for the chemical under
review. To the extent practicable, effort
should be made to review such informa-
tion before deciding upon the possible
mode of chemical action underlying the
thyroid tumors and their consequences for
risk assessment.
The procedures and considerations
developed in this report embody current
scientific knowledge ofthyroid carcinogen-
esis and evolving science policy positions.
Should significant new information become
available that would change these positions,
the EPA will update its science policy posi-
tions accordingly.
Evidence forAntithyroidActivity
Data needs. Different types of information
on a chemical may indicate that it has
antithyroid activity, that is, whether it
works via disruption of thyroid-pituitary
status. These include effects manifest in the
thyroid gland per se, various tissues periph-
eral to the thyroid, and/or the liver. All
available factors are assembled into an over-
all evaluation of the likelihood that the
chemical is acting via disruption ofthe thy-
roid-pituitary axis. A number ofchemicals
have been assessed (3).
Special mechanistic studies are needed
to demonstrate chemically induced pertur-
bations in thyroid-pituitary functioning.
Repeat dose (e.g., 2-4 week and 13 week)
studies that have simultaneously evaluated a
number of end points can often provide
critical information for evaluating qualita-
tively whether antithyroid activity exists,
the cause of the activity, and quantitatively
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what dose-response relationships may be
appropriate. Such studies should be careful-
ly designed to encompass multiple doses
from above those clearly associated with
tumors in chronic studies down to those
below which there is no indication of dis-
turbance in critical thyroid-pituitary para-
meters, so that dose-response relationships
can be defined. Special attention should be
given to the time of sampling of thyroid
and pituitary hormones because ofthe com-
pensatory action of homeostatic mecha-
nisms and the difficulty in discerning
changes after compensation occurs.
Hormone sampling should also be conduct-
ed at the same time during the course ofa
day to minimize circadian hormonal fluctu-
ations, and efforts should minimize stress in
handling animals. Effects measured only at
the end ofchronic rodent studies are often
difficult to evaluate and, alone, seldom pro-
vide adequate information.
The determination of the antithyroid
activity of a chemical requires empirical
demonstration of the following items.
Demonstration of increases in thyroid
growth and changes in relevant thyroid and
pituitary hormones are considered to be the
most important. Location of the site(s) of
antithyroid action documents where in the
body the chemical under assessment leads to
perturbations in thyroid-pituitary function-
ing. Dose correlations among various effects
determine where the growth curve for the
thyroid gland deviates from the normal pat-
tern ofcell replacement and how this relates
to doses producing tumors. Reversibility of
effects following treatment cessation during
the early stages of disruption of the thy-
roid-pituitary axis shows that permanent,
self-perpetuating processes have not been set
into motion.
The following three items are desirable
in determining antithyroid activity: lesion
progression, structure-activity analysis, and
other studies. Each provides supporting
information that can add profoundly to the
assessment ofan agent's ability to produce
antithyroid effects.
Increases in cellular growth (evidence
required). Agents that affect thyroid-pitu-
itary function may stimulate thyroid
enlargement. Most parameters commonly
measured include, but are not limited to,
increases in absolute or relative thyroid
gland weight or histological indications of
cellular hypertrophy and hyperplasia, mor-
phometric documentation of alteration in
thyroid cellular components, and changes
in the proliferation offollicular cells detect-
ed by DNAlabeling or mitotic indices.
Hormone changes (evidence required).
With a disruption in thyroid-pituitary func-
tioning, there is typically a reduction in both
circulating serum T4 and T3 concentrations
and an increase in TSH levels within days or
a few weeks ofchemical administration. In
some cases, T4 levels may be lowered while
T3 levels are maintained within normal lim-
its. In addition, sometimes hormone levels
may return to normal over time for mild
goitrogenic agents because ofthe homeostat-
ic compensatory increase in thyroid activity
and mass. Statistical tests can help evaluate
the significance ofhormone perturbations,
but it is the constellation ofchanges in both
thyroid and pituitaryhormones that indicate
whether the negative feedback loop between
the thyroid and hypothalamus/pituitary has
beenperturbed.
Site ofaction (evidence required).
Chemicals that produce thyroid tumors
alone or after administration ofa mutagenic
initiator produce interference with
thyroid-pituitary function at various sites in
the body (Fig. 3). Effects have been found at
one or more of the following anatomical
locations: intrathyroidal and various
extrathyroidal sites, induding the liver and
other sites. Clues to the site of action can
sometimes be deduced by analysis of struc-
turally related compounds. Generally,
enough information on a chemical should be
given to be able to identifythesites that con-
tribute the major effect on thyroid-hypo-
thalamus-pituitary function. Given experi-
ence to date, it appears that most often the
liveris the siteofaction, followed bythethy-
roid, where thyroid peroxidase is affected;
othersites ofaction seem to beless common.
Intrathyroidal. Several different effects
in the thyroid gland have been associated
with the development ofantithyroid activity
and the formation of thyroid tumors in
rodents. Iodide pump inhibition by chemi-
cals like thiocyanate and perchlorate ions
leads to a decrease in uptake of inorganic
iodide into the thyroid gland. Thyroid per-
oxidase inhibition blocks the incorporation
ofactive iodide into iodotyrosines and their
coupling to form the nascent thyroid hor-
mones. Agents that are known to reversibly
orirreversibly inactivate this enzyme include
various thionamides such as 6-propylth-
iouracil and ethylene thiourea, certain aro-
matic amines, e.g., some of the sulfon-
amides, and miscellaneous compounds such
as amitrole. Toxicity to thyroid cells, as has
been seen with polychlorinated biphenyls,
mayaffect thegland's ability to manufacture
and secrete thyroid hormones. Inhibition of
thyroid hormone release, with agents like
lithium and excess iodide, results in a reten-
tion of hormones within the colloid and a
paucityreleased into thecirculation (81).
Extrathyroidal. Several tissues and
organs ofthe body, including skeletal mus-
cle, kidneys, and liver, contain different
deiodinases that remove iodine atoms from
thyroid hormones. Inhibition of 5'-mon-
odeiodinase, the enzyme that normally con-
vertsT4 to T3, leads to a reduction in circu-
latingT3 and an increase in the rT3 level via
3 -deiodination. Compounds like FD&C
Red No. 3 (erythrosine), iopanoic acid, and
6-propylthiouracil act by competitive inhi-
bition ofthis enzyme or interaction with its
sulfhydryl cofactor. The deiodinase system
in the pituitary is somewhat different from
that in the periphery and may respond dif-
ferently to certain chemicals (82).
A significant amount of thyroid hor-
mone normally is metabolized by the liver.
Certain chemicals induce liver microsomal
enzymes and enhance thyroid hormone
metabolism and removal. T4 conjugation
with glucuronic acid is enhanced by agents
that induce hepatic glucuronosyl transferase
(19). In these cases, thyroid hormone may
also show increased binding to hepatocytes,
increased biliary excretion, and increased
plasma clearance. Other common manifes-
tations of microsomal induction include
enlargement of hepatocytes in the cen-
trolobular region, an increase in hepatic cell
smooth endoplasmic reticulum, an increase
Figure 3. Antithyroid effects that influence thyroid carcinogenesis. Abbreviations: TH, thyroid hormone;
TSH, thyroid stimulating hormone.
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in P450-associated metabolism of various
chemical substrates, and an increase in bil-
iaryflow.
Disparate chemical and functional class-
es like polyhalogenated hydrocarbons (e.g.,
2,3,7,8-tetrachlorodibenzo-p-dioxin), barbi-
turates (e.g., phenobarbital), and various
individual compounds (e.g., the pesticide
clofentezine, the drug spironolactone, and
the histamine antagonist SK&F 934790) are
known to enhance thyroid hormone excre-
tion via effects on microsomal enzymes.
Conjugation also may occur with sulfate,
usually associated with deiodination; deami-
nation, oxidative decarboxylation, and
ether-link cleavage are minor degradative
pathways. Interestingly, phenobarbital has
been shown to be a promoter in the rodent
thyroid (35), but there is no indication it
produces thyroid cancer in humans (83).
Chemicals may bind thyroid hormone
receptors and produce certain effects. For
instance, agents (e.g., salicylates) can dis-
place thyroid hormone from plasma carrier
proteins and result in reductions in effective
thyroid hormone (84,85). They could bind
receptors in target organs (e.g., pituitary)
but result in inactive complexes. These pos-
sibilities plus other potential sites of action
(e.g., affecting TRH, thyroid hormone
responsive elements on the DNA) may be
conceived as influencing thyroid-pituitary
functioning.
Dose correlations (evidence required).
Confidence in an antithyroid mode of
action is enhanced by evidence ofa correla-
tion between doses of a chemical that do
and do not jointly perturb thyroid-pitu-
itary hormone levels, produce various his-
tological changes in the thyroid, orproduce
other effects, including thyroid cancer.
These are important steps in evaluating the
significance ofthyroid-pituitary disruption
in thyroid carcinogenesis and in evaluating
dose-response relationships.
Reversibility (evidence required).
Chemicals working through an antithyroid
mode of action induce changes in thyroid
cell morphology and number and in thy-
roid-pituitary hormones that are reversible
upon cessation ofchemical dosing.
Lesion progression (evidence desirable).
Evidence for a progression ofhistological
lesions over time is commonly noted during
the carcinogenic process. These include cel-
lular hypertrophy and hyperplasia, followed
by focal hyperplasia and, eventually, neopla-
sia (benign andpossiblymalignant tumors).
Structure-activity analyses (evidence
desirable). Analysis of chemical structure
may show that an agent belongs to a class
ofcompounds that induces thyroid tumors
via thyroid-pituitary imbalance (e.g.,
agents that inhibit thyroid peroxidase, liver
microsomal enzyme inducers). This allows
for the scientific inference that the chemi-
cal under review may act similarly. In addi-
tion, generic information developed on a
group ofanalogues can be used to support
the assessment ofthe agent under review.
Otherstudies (evidence desirable). Many
other studies bearing on thyroid-pituitary
imbalance can provide a range of findings
from strong ancillary information to only
suggestive indications. For example, a few of
these studies indude suppression ofinduced
effects by concurrent administration ofthy-
roid hormone; absence of initiating activity
but presence of promoting activity in two-
stage carcinogenicity tests; localization ofcer-
tain chemicals in the thyroid (e.g., thion-
amides); influences on hypothalamic respon-
siveness to thyroid hormone levels and out-
put ofTRH; changes in TSH mRNA tran-
scripts in the pituitary; and alteration ofthy-
roid hormone nuclear receptor number or
synthesis.
Other Modes ofCarcinogenic Action
Another critical element in the evaluation
of a thyroid carcinogen is a determination
of whether mutagenicity may account for
the observed tumors. Primary emphasis
should be placed on those end points that
have mechanistic relevance to carcinogenic-
ity. DNA reactivity is a prime predictor of
potential mutagenic carcinogenicity. Many
of these compounds belong to particular
chemical classes (e.g., aromatic amines,
nitrosamines, polyaromatic hydrocarbons).
These chemicals or their metabolites bind
to DNA, and they often induce gene muta-
tions and structural chromosome aberra-
tions. In recognition that organs and tis-
sues may have unique metabolic activity, it
is helpful to know in addition to tradition-
al short-term test results whether there is
evidence ofDNA reactivity in target tissues
(e.g., DNA adducts, unscheduled DNA
synthesis, single strand breaks).
Mutagenic effects other than those
associated with direct DNA reactivity need
to be carefully evaluated in regard to their
mechanistic implications; some may have
different cancer dose-response considera-
tions than do direct DNA reactive agents.
These effects include the ability of the
chemical under review to induce indirect
effects on DNA, such as through influence
on the cell division spindle or production
of reactive oxygen. Agents also should be
evaluated for the presence of structural
alerts that are often predictive of chemical
reactivity or potential carcinogenicity. All
of these findings are then melded into an
overall appraisal of an agent's ability to
influence genetic processes relevant to car-
cinogenesis in the thyroid or other sites.
It is possible that information on car-
cinogenic modes ofaction other than muta-
genicity or thyroid-pituitary derangement
will become available. Ifso, this information
also needs to be incorporated on a case-by-
case basis into the evaluation ofa chemical's
abilityto produce tumors ofthe thyroid (and
ofothersites).
Dose-Response Considerations
Evaluation of potential dose-response rela-
tionships for thyroid tumors depends on an
evaluation ofthe chemical's expected mode
of carcinogenic action. Major determina-
tions include whether the thyroid tumors
appear to be due, at least in part, to thy-
roid-pituitary imbalance and whether other
modes of action (e.g., relevant mutagenici-
ty) may be pertinent to their formation.
Other case-specific factors may provide cru-
cial information, such as the extent to
which data gaps and uncertainties prevail. A
rationale should accompany the selection of
any dose-response method. Guidance is
provided below to illustrate ways to evaluate
data and make judgments about potential
thyroid cancer dose-response relationships.
High to low dose extrapolation. If
antithyroid influences areoperativeinthefor-
mation of thyroid tumors, attention should
be directed to biologically based procedures
that embody the mechanistic influences, if
they are available. In their absence, default
procedures should be employed that incorpo-
rate nonlinear orlinearconsiderations. When
thyroid-pituitary imbalance is not operative,
other modes ofaction or default considera-
tions should be used; generally low-dose lin-
ear extrapolations are appropriate. All extrap-
olation procedures should be consistent with
the guidance given in EPA cancer risk assess-
ment guidelines. Finally, when thyroid
tumors seem to arise from both a chemical's
antithyroid activity and its mutagenic poten-
tial, dose-response relationships may be pro-
jected in ways that express concerns for both
possiblemodesofaction.
When tumors other than thyroid follic-
ular cell (and related pituitary) tumors are
found along with thyroid tumors, mode of
action and other considerations should help
guide the selection of the appropriate
dose-response extrapolation method(s).
Separate dose-response extrapolations may
apply for the different tumor types, depend-
ing on the specifics ofthe case.
Biologically based. Optimally, mechanis-
tic considerations that underliethyroid tumor
formation should be incorporated into bio-
logically based extrapolation models. They
should indude physiologicallybased pharma-
cokinetic considerations for the chemical and
its interactions with and effects upon cells.
The trouble is that generic biologically based
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dose-response extrapolation models have yet
to be developed and validated for the thy-
roid. Fortunately, work in this area is begin-
ning, and a model has been developed to
explain effects associated with 2,3,7,8-tetra-
chlorodibeno-p-dioxin (86). Until other
mechanistic models become generally avail-
able and chemical-specific data have been
produced, the EPA assessments will employ,
as discussed below, one ofthree default pro-
cedures in its evaluation of thyroid cancer
risks: nonlinear, linear, or both nonlinear
andlinear.
Nonlinear. For cases in which tumors
arise from chemically induced disturbances
in thyroid-pituitary functioning, tumors are
considered to be secondary to the adverse
effects on thyroid gland function that pre-
cede them. As exposures to such agents
decrease, the likelihood of cancer decreases;
risks may be seen as minimal at doses at
which there is no effect on thyroid-pituitary
homeostasis. Generally, homeostasis is con-
sidered to apply when serum T4, T3, and
TSH levels and thyroid and pituitary mor-
phology and growth are within their normal
limits. Risk assessments on agents should
contain case-specific and generic informa-
tion that support the contention that non-
linear dose-response relationships apply.
Empirically there is some support for
thyroid follicular cell tumors having a
dose-response curve that is less than linear
(curvilinear upward). Slope functions were
calculated using the Weibull model to give
some indication of the shape of the
dose-response curve and the rodent tumor
incidence database of the National Cancer
Institute/National Toxicology Program.
Incidence for tumors in general was more
consistent with a quadratic rather than a
linear dose-response curve shape (87,88).
However, when slopes for thyroid follicular
cell tumors were compared with those of
thyroid C cell tumors and all other tumor
sites, those from the thyroid follicular cells
were even more curvilinear than the others
(Portier, personal communication).
One argument for assuming low-dose
linearity in dose-response assessments is the
concept of additivity to background. If a
given chemical acts in the same way or aug-
ments an endogenous or exogenous back-
ground factor that contributes to tumor
development, the effect ofthe chemical will
add to that of the background factor. The
result is low-dose linearity up to at least a
doubling of the background rate (85). The
concept may not be applicable to certain
processes subject to hormonal regulation,
such as with the thyroid gland. Normally
the level ofcirculating thyroid hormone is
adjusted carefully by the negative feedback
with the pituitary. Elevations and reductions
in thyroid hormone are met with adjust-
ments in the amount ofTSH released from
the pituitary so as to bring thyroid hormone
values back into the normal range. These
excursions are not part of an ongoing car-
cinogenic process; instead, they represent
the body's means of maintaining thyroid
hormone homeostasis. Small doses of a
potentially antithyroid chemical may not
result in any perturbation in hormone levels
or stimulation of thyroid follicular cell
growth simply because homeostatic mecha-
nismswill drive thyroid hormone levels back
into the normal range.
The EPA acknowledges that it may be
difficult to establish a precise dose where
there is negligible response for a specific tox-
icologic effect given the sensitivity ofmeth-
ods to evaluate various parameters and the
variability in measurement ofend points. In
recognition ofthis, it is incumbent upon the
scientific community to help in the transfer
of various molecular techniques from the
research laboratory to testing facilities (e.g.,
measurement of hormone receptor mRNA
production and receptor content, occupan-
cy, and turnover) that may be more sensitive
indicators ofthyroid-pituitary malfunction.
The way the EPA has dealt with nonlin-
ear phenomena is to express concern for
human exposure (risk) as a margin ofexpo-
sure (MOE), the ratio between a dose point
ofdeparture for the critical effect and the rel-
evant estimate of anticipated human expo-
sure (incorporating dose, frequency, and
time). Large MOEs are attended with less
concern than are small ones. Traditionally,
the point of departure is expressed as a no
observed adverse effect level (NOAEL), and
the critical effect is the relevant toxicological
end point occurring at the lowest doses in a
toxicological study. More recently, alterna-
tives to the NOAEL have been proposed to
serve as points ofdeparture for MOE calcu-
lation. In April 1996, the EPA proposed a
revision ofits existing cancer risk assessment
guidelines (4. A dose point ofdeparture is
determined by extrapolating effects in the
observed part ofthe dose-response curve. It
is used, depending on the expected mode(s)
ofaction, as the starting point for either lin-
ear extrapolation to the origin or calculation
ofan MOE in the case ofnonlinear extrapo-
lation. Generally, tumor or nontumor end
point (e.g., hyperplasia) incidence is extrapo-
lated to the 10% effectlevel. The 95% confi-
dence levels are placed on that dose. The
lower 95% confidence limit on that dose
maybe usedas the pointofdeparture forrisk
estimation below the observed data. There is
some discussion about using the point esti-
mate at the 10% effect level in lieu ofthe
lower bound estimate in the proposal. Other
means of determining departure points are
also proposed (2). Final cancer guidelines
will darify these points. Procedures should
be employed for thyroid tumors that are
consistent with EPA cancer risk assessment
guidelines andpractices that areapplicable at
the time.
Assessments should include adequate
information to aid in interpreting the sig-
nificance of MOEs, such as taking into
consideration the variability in sensitivity
among individuals within a species, the
sensitivity ofhumans relative to experimen-
tal animals, and other strengths, weakness-
es, and uncertainties that are part of the
assessment. Decision makers must then
judge the adequacy of the MOE for their
risk management purposes.
Low-dose linear. For those assessment
cases in which thyroid tumors do not seem
to be due to thyroid-pituitary imbalance
(e.g., mutagenic agents), existing case-specif-
ic mode-of-action information and default
considerations should be used to develop
dose-response relationships. In other cases,
there may be an absence ofmode-of-action
information for an agent. Generally a low-
dose linear default for the thyroid tumors
may be contemplated in these two circum-
stances in accordance with current EPApro-
cedures. Recent cancer risk assessment
guideline proposals suggest that linear
extrapolation would involve calculation ofa
dose point ofdeparture with a straight line
extrapolation from there to theorigin (2).
Low-dose linear and nonlinear. Finally,
careful review is warranted when both
antithyroid and other determinants seem to
applyto theobserved thyroid tumors, such as
when there are certain mutagenic influences
(e.g., structural chromosome aberrations).
Judgments with accompanying scientific rea-
soning should be presented on the most
appropriate way(s) to evaluate thyroid risk:
either linear or nonlinear or, when the two
positions are about equally tenable, both.
When both procedures are presented, asses-
sors should state the relative merits ofeach
procedure. In some cases, one ofthe two
methods may be preferable and should be
given more weight; the rationale for condu-
sions should be expresslypresented. Projected
risks using linear extrapolation often give rise
to concerns at doses lower than those when
nonlinear techniques are applied. Thus, these
two techniques usuallycan be seen as putting
lowerandupperbounds onexposures ofcon-
cern. Assessments should indude guidance
for decision makers in interpreting concerns
for exposure when both extrapolation tech-
niques arepresented.
Endpoints to be employed Optimally,
one would have access to data on various
preneoplastic end points that would be eval-
uated following short-term (e.g., 2-4 week)
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and subchronic (e.g., 13 week) studies and
comparedwith the doses that have produced
tumors in chronic studies. End points that
should regularly be evaluated and presented
in dose-response analyses include 1) changes
in levels ofT4 and T3; 2) increases in TSH;
3) the incidence of thyroid follicular cell
hypertrophy, hyperplasia, and neoplasia; 4)
increases in cell proliferation and thyroid
weight; and 5) specific end points associated
with thyroid-pituitary disturbance at the
site(s) ofchemical action (e.g., inhibition of
thyroid peroxidase, increased metabolism
and clearance of thyroid hormone). A host
ofother effects as discussed above could be
monitored in the thyroid, pituitary, or thy-
roid hormone-responsive organs and includ-
ed on a case-by-case basis. Care should be
taken to ensure that studies to evaluate these
parameters are conducted for adequate peri-
ods of time and at doses that clearly define
dose-response relationships. Attention also
needs to be given to procedures that help to
reduce the variability in responses among
animals (e.g., time and means ofanimal sac-
rifice and tissuesampling).
Estimation ofpoints ofdeparture. For
the important toxicity studies, a point of
departure (e.g., NOAEL) is determined for
each thyroid toxicity end point and expo-
sure duration. Doses associated with tumors
should also be noted. The departure point
may be a study dose or an estimated dose.
For instance, when data permit, the depar-
ture point can be estimated by extrapola-
tion of doses associated with observed
responses (e.g., TSH levels) to those attend-
ed with no significant deviation from the
control range. In other cases, an appropriate
observed study NOAEL may be selected or
other procedures in accordance with EPA
guidance maybe used.
Considerations for the selection of the
critical end point to be used to project thy-
roid cancerrisk (i.e., calculation oftheMOE)
include 1) the nature ofthe end point and its
relationship to theperturbations in endocrine
balance and carcinogenicity; 2) the presence
of good dose-response or dose-severity of
effect relationships; 3) the sensitivity of the
end point vis-a-vis otherpotential end points;
and 4) the length ofthedosingperiodand its
relevance to making judgments about the
consequences ofpotential chronicexposures.
Interspecies Extrapolation
Many considerations are relevant in
attempting to extrapolate thyroid carcino-
genic effects in experimental animals to
humans. The relative sensitivity of humans
and rodents to the carcinogenic effects of
elevated TSH are not firmlyestablished, but
important observations have been made.
Given that the rodent is a sensitive model
for measuring the carcinogenic influences of
TSH and that humans appear to be less
responsive, one would expect that projec-
tions of potential risk for rodents would
serve as conservative potential indicators of
risks for humans.
Rodent cancer studies typically include
doses that lead to toxicity, induding pertur-
bation in thyroid-pituitary functioning,
over alifetime. The relevance ofsuch experi-
mental conditions to anticipated human
exposure scenarios (i.e., dose, frequency, and
time) should be considered and presented in
the final characterization of risk. This is
especially true because thyroidal effects are
not necessarily expected at all doses. In addi-
tion, chemically induced effects that are pro-
duced by short-term disruption in thy-
roid-pituitary functioning appear to be
reversible when thestimulus is removed.
Although it appears that humans are less
sensitive to the carcinogenic perturbations
of thyroid-pituitary status than rodents
(e.g., iodide deficiency), such determina-
tions should be made on a case-by-case
basis. This would depend upon a host of
factors involving the agent, including the
depth and breadth ofthe database, the con-
gruence of the information supporting a
given mode of action, and the existence of
information on humans. Decision makers
should be apprised ofrisk assessment judg-
ments and their rationales. In the absence of
chemical-specific information, the default
position is that humans should be consid-
ered to be as sensitive to carcinogenic effects
as are rodents. That is to say, a factor ofone
would be used when extrapolating effects in
rodents to those in humans.
Human intraspecies evaluations. Thyroid
hormones are regulated within rather narrow
ranges. Normal human serum values are as
follows: T4, 4-11 pg/dl and T3, 80-180
ng/dl; TSH levels extend over a broader
range: 0.4 to 8 pU/ml due to the incorpora-
tion in recent years of more sensitive labora-
tory methods that have extended the normal
range to lower values (90,91). To the extent
that data exist in humans as to their thy-
roid-pituitary status, one should carefully
review central value parameters between
chemically exposed and unexposed groups as
well as the distribution ofvalues between
bothgroups.
Extended deviations in human thyroid
hormone levels either above or below the
normal range are associated with the disease
states hyperthyroidism and hypothyroidism,
respectively. In the United States, most cases
are associated with some autoimmune prob-
lem. Worldwide, iodide deficiency is the
most prominent cause ofthyroid diseasegen-
erally and hypothyroidism specifically.
People develop characteristic symptoms and
signs that readily cause them to seek medical
attention. The goal oftherapy for such con-
ditions is to bring persons back into normal
thyroid-pituitary balance, which secondarily
wouldgreatlyminimize anypotential forcar-
cinogenic effects. Overt hypothyroidism,
with reduced thyroid hormone and increased
TSH levels, requires treatment; it has an
incidence ofabout 0.2% in women and less
in men. Subclinical hypothyroidism may
have an incidence of 5% among women.
Men are affected less often; incidence
increases significantly with age. There is not
agreement as to whether these people need
treatment (92). Some with hypothyroidism
may go for some time before diagnosis and
treatment. The possible consequences of
chemical exposure on this subpopulation of
individuals maywarrant consideration.
The human thyroid is susceptible to
ionizing radiation, the only known human
thyroid carcinogen. Children are more sen-
sitive than adults to the carcinogenic effects
of ionizing radiation (41,53). In keeping
with the EPA position on the evaluation of
childhood risks (93), the impact of muta-
genic chemicals that produce thyroid
tumors should be evaluated in context of
the information available on the subject as
well as agent-specific information. The
extent to which a chemical may act as ion-
izing radiation does should be evaluated on
a case-by-case basis and factored into deci-
sions accordingly. It seems possible that
chemicals producing mutagenic effects like
those ofradiation may pose some accentu-
ated risk to children. More research is
needed in this area (94).
Combinedeffects. It is notknown ifthere
are human subpopulations that are sensitive
to thyroid cancer development from expo-
sure to antithyroid chemicals. Seemingly, the
thyroid status ofpersons living in an iodide-
deficient area or those who are hypothyroid
due to other causes may further be harmed
by simultaneous exposure to naturally occur-
ringchemicals orxenobiotics that can further
disrupt thyroid-pituitary functioning (95).
This potential to possibly increase cancer risk
following chemical exposure should be kept
in mind in evaluating the composition of
human populations, the numbers and nature
of sensitive individuals, the magnitude and
pattern of chemical exposure, estimates of
risk to the general population, and the
potential risk consequences to persons with
some increase insensitivity.
In addition to possible sensitive sub-
populations, persons may be exposed to
more than one antithyroid chemical at a
time and by more than one route ofexpo-
sure. These combined exposures may wors-
en thyroid-pituitary status and influence
thyroid cancer potential (96). To the
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extent practicable on a case-by-case basis,
consideration should be given to combined
exposures to chemicals that influence thy-
roid-pituitary functioning. Attention can
be directed toward 1) an understanding of
whether the chemicals affect the same or
different sites of antithyroid action, 2)
whether mutagenicity or other modes of
action may be operative, and 3) the ways
various antithyroidal and other effects may
combine to influence potential cancer risks
by the same and different routes of expo-
sure. Some guidance for evaluating these
cases is provided in the EPA mixtures
assessment guidelines (94).
Unlike tumors at many sites, modes of
action for thyroid follicular cell tumors can
be readily explored through laboratory
experimentation. By using this cancer
mode-of-action information alongwith con-
siderations about intraspecies and intere-
species variability, chemicals can be assessed
as to the consequences ofhuman exposure.
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